Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1998 1
1999 5
2000 14
2001 3
2002 6
2003 4
2004 8
2005 6
2006 3
2007 2
2008 1
2010 2
2014 1
2015 3
2016 1
2017 4
2018 3
2019 3
2020 2
2021 6
2022 9
2023 12
2024 11
2025 17
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean ishimura h[au] (64 results)?
Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma.
Ishihara H, Omae K, Nemoto Y, Mizoguchi S, Katsurayama N, Nakayama T, Fukuda H, Yoshida K, Shimmura H, Hashimoto Y, Iizuka J, Kondo T, Takagi T. Ishihara H, et al. Among authors: shimmura h. Urol Oncol. 2025 Oct;43(10):598.e1-598.e10. doi: 10.1016/j.urolonc.2025.06.019. Epub 2025 Aug 5. Urol Oncol. 2025. PMID: 40754547
First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.
Ishihara H, Omae K, Nemoto Y, Ishiyama R, Tachibana H, Nishimura K, Ikeda T, Kobari Y, Fukuda H, Yoshida K, Shimmura H, Hashimoto Y, Iizuka J, Kondo T, Takagi T. Ishihara H, et al. Among authors: shimmura h. Int J Clin Oncol. 2024 Apr;29(4):473-480. doi: 10.1007/s10147-024-02471-w. Epub 2024 Feb 12. Int J Clin Oncol. 2024. PMID: 38345708
Intensive blood pressure lowering.
Sonoda Y, Higuchi A, Morita T, Mori J, Shimmura H. Sonoda Y, et al. Among authors: shimmura h. Lancet. 2016 Jun 4;387(10035):2291. doi: 10.1016/S0140-6736(16)30688-2. Lancet. 2016. PMID: 27302267 No abstract available.
Outcomes of Enfortumab Vedotin Treatment in Patients Ineligible for the EV-301 Trial.
Nakamura K, Kobari Y, Ishiyama Y, Kondo H, Inakawa T, Nemoto Y, Fukuda H, Yoshida K, Iizuka J, Shimmura H, Kobayashi H, Hashimoto Y, Ishida H, Kondo T, Takagi T. Nakamura K, et al. Among authors: shimmura h. In Vivo. 2025 Sep-Oct;39(5):2766-2776. doi: 10.21873/invivo.14075. In Vivo. 2025. PMID: 40877170 Free PMC article.
Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma.
Ishihara H, Nishimura K, Nemoto Y, Mizoguchi S, Nakayama T, Fukuda H, Shimmura H, Hashimoto Y, Yoshida K, Iizuka J, Kondo T, Takagi T. Ishihara H, et al. Among authors: shimmura h. Jpn J Clin Oncol. 2026 Jan 9;56(1):73-79. doi: 10.1093/jjco/hyaf152. Jpn J Clin Oncol. 2026. PMID: 41025729
Essential medicines for universal health coverage.
Tanimoto T, Tsuda K, Kurokawa T, Mori J, Shimmura H. Tanimoto T, et al. Among authors: shimmura h. Lancet. 2017 May 13;389(10082):1880-1881. doi: 10.1016/S0140-6736(17)31211-4. Epub 2017 May 11. Lancet. 2017. PMID: 28513444 No abstract available.
129 results